LON:BPCR BioPharma Credit (BPCR) Share Price, News & Analysis GBX 0.97 +0.01 (+0.83%) As of 07/24/2026 12:05 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsBuy This Stock About BioPharma Credit Stock (LON:BPCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioPharma Credit alerts:Sign Up Key Stats Today's Range 0.96▼ 0.9750-Day Range 0.94▼ 0.9752-Week Range 0.86▼ 1Volume3.76 million shsAverage Volume1.49 million shsMarket Capitalization£10.86 millionP/E Ratio0.08Dividend Yield7.23%Price TargetN/AConsensus RatingN/A Company Overview BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in London, the United Kingdom. Read More Receive BPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPharma Credit and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPCR Stock News HeadlinesMineralys Therapeutics Announces $200 Million Royalty Repurchase and Secures $500 Million Debt FacilityJune 3, 2026 | quiverquant.comQEsperion Therapeutics to Be Acquired by ARCHIMED in Up to $1.1 Billion Transaction, Shareholders to Receive $3.16 Per Share in CashMay 1, 2026 | quiverquant.comQUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income Plan - direct ownership in 14 entities controlling U.S. pipelines, terminals, and processing plants, targeting 10% annually. The plan issues 42 payouts per year and is on pace to distribute $53 billion in 2025 - a record. The next distribution drops in days.July 26 at 1:00 AM | Freedom Financial (Ad)UroGen Pharma Ltd. Enhances Financial Position with Amended Loan Agreement for Up to $250 MillionMarch 2, 2026 | quiverquant.comQ3 Undiscovered Gems In The United Kingdom To Consider For Your PortfolioDecember 30, 2025 | finance.yahoo.comExploring Undiscovered Gems in the UK for December 2025December 1, 2025 | uk.finance.yahoo.comUndiscovered Gems In United Kingdom Highlighted By 3 Promising StocksOctober 31, 2025 | finance.yahoo.comBioPharma Credit buys back $50 mln shares, reports $72.8 mln profit in first halfSeptember 22, 2025 | investing.comSee More Headlines BPCR Stock Analysis - Frequently Asked Questions How have BPCR shares performed this year? BioPharma Credit's stock was trading at GBX 0.92 at the beginning of the year. Since then, BPCR stock has increased by 5.7% and is now trading at GBX 0.97. How do I buy shares of BioPharma Credit? Shares of BPCR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of BioPharma Credit own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioPharma Credit investors own include AFPO.L (AFPO), Altius Minerals (ATUSF), NexGen Energy (NXE), Premier African Minerals (PREM) and 21512 (SAT.L) (SAT). Industry, Sector and Symbol Stock ExchangeLON SectorFinancial Services Industry Asset Management Sub-IndustryN/A Current SymbolLON:BPCR CIKN/A Webwww.bpcruk.com Phone44 13 9247 7500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 11.40 Trailing P/E Ratio0.08 Forward P/E RatioN/A P/E GrowthN/ANet Income£10.42 billion Net Margins92.62% Pretax MarginN/A Return on Equity11.29% Return on Assets4.98% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio14.07 Sales & Book Value Annual Sales£132.06 million Price / Sales0.08 Cash FlowGBX 0.81 per share Price / Cash Flow1.19 Book ValueGBX 98.56 per share Price / Book0.01Miscellaneous Outstanding Shares1,122,193,000Free FloatN/AMarket Cap£10.86 million OptionableNot Optionable Beta0.21 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (LON:BPCR) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe Weekly Options Trick Wall Street Doesn't AdvertiseThe most profitable trading desks don't guess market direction, they collect income regardless of it. A 25-yea...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPCR Stock Alerts